Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Dec 13;51(11):1-10.

Adult blood lead epidemiology and surveillance--United States, 1998-2001

Robert J Roscoe  1 , Wayne Ball, John J Curran, Carol DeLaurier, Myron C Falken, Rose Fitchett, Mary Lou Fleissner, Amy E Fletcher, Susan J Garman, Rita M Gergely, Barbara T Gerwel, Judith E Gostin, Ezatollah Keyvan-Larijani, Richard D Leiker, J P Lofgren, Deborah R Nelson, Susan F Payne, Richard A Rabin, Diana L Salzman, Kristina E Schaller, Amy S Sims, Joshua D Smith, Edward M Socie, Marie Stoeckel, Robert R Stone, Stephen G Whittaker
Affiliations
  • PMID: 12528812
Free article

Adult blood lead epidemiology and surveillance--United States, 1998-2001

Robert J Roscoe et al. MMWR Surveill Summ. .
Free article

Abstract

Problem/condition: Elevated blood lead levels (BLLs) in adults can damage the cardiovascular, central nervous, reproductive, hematologic, and renal systems. The majority of cases are workplace-related. U.S. Department of Health and Human Services recommends that BLLs among all adults be reduced to < 25 microg/dL. The highest BLL acceptable by standards of the U.S. Occupational Safety and Health Administration is 40 microg/dL. The mean BLL of adults in the United States is < 3 microg/dL.

Reporting period: This report covers cases of adults (aged > or = 16 years) with BLLs > or = 25 microg/dL, as reported by 25 states during 1998-2001.

Description of system: Since 1987, CDC has sponsored the state-based Adult Blood Lead Epidemiology and Surveillance (ABLES) program to track cases of elevated BLLs and provide intervention consultation and other assistance. Overall ABLES program data were last published in 1999 for the years 1994-1997. This report provides an update with data from 25 states reporting for > or = 2 years during 1998-2001. During that period, the ABLES program funded surveillance in 21 states - Alabama, Arizona, Connecticut, Iowa, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Washington, Wisconsin, and Wyoming. Four additional states - California, Nebraska, New Hampshire, and Utah contributed data without CDC funding.

Results: During 1998-2001, the overall program's annual mean state prevalence rate for adults with BLLs > or = 25 microg/dL was 13.4/100,000 employed adults. This compares with 15.2/100,000 for 1994-1997. Yearly rates were 13.8 (1998), 12.9 (1999), 14.3 (2000), and 12.5 (2001). For adults with BLLs > or = 40 microg/dL, the overall program's annual mean state prevalence rare during 1998-2001 was 2.9/ 100,000 employed adults. This compares with 3.9/100,000 for 1994-1997. Yearly rates were 3.3 (1998), 2.5 (1999), 2.9 (2000), and 2.8 (2001).

Interpretation: Although certain limitations exist, the overall ABLES data indicate a declining trend in elevated BLLs among employed adults.

Public health actions: ABLES-funded states increased from 21 to 35 in 2002, and more detailed reporting requirements were put into effect. These, and other improvements, will enable the ABLES program to work more effectively toward its 2010 target of eliminating all cases of BLLs > or = 25 microg/dL in adults caused by workplace exposures.

PubMed Disclaimer